Therapeutic Response

ER negative, HER2-negative, and PR negative status confers therapeutic sensitivity to Carboplatin in combination with Cyclophosphamide, Doxorubicin, and Paclitaxel in patients with Invasive Breast Carcinoma.

Statements

Source and description